Research Results of 3rd Dose Coronavirus Vaccines Announced

It has been revealed in recent months that the Sinovac vaccine, which is produced in China and also known as CoronaVac, lost its protective effect after it was applied. Thereupon, many scientists called for the application of the 3rd dose of BioNTech vaccine, and the 3rd dose vaccination campaign was started. Months passed, and a study conducted in Turkey revealed whether the idea of ​​the 3rd dose worked.

A study conducted on healthcare workers at Hafsa Sultan Hospital found that all those who received the 3rd dose of the vaccine in question. has a protective amount of antibodies appeared. Thus, it became clear that the idea of ​​a 3rd dose, albeit only for Sinovac, makes sense and can be defined as the default dose amount.

3rd dose was successful:

1053 healthcare professionals working at Manisa Celal Bayar University Faculty of Medicine Hafsa Sultan Hospital were included in a study to see the effect of 2 doses of Sinovac and 1 dose of BioNTech. It was seen in the study that those who received 2 doses of the inactivated vaccine were followed for 6 months and the result was observed after taking the 3rd dose. The 3rd dose application fully achieved its purpose. The faculty members of the MCBÜ Faculty of Medicine, Department of Medical Microbiology, Public Health and Infectious Diseases, who conducted the study in which the disease frequency and antibody level of the participants were supervised; He made the following statements about the data they obtained:

“In those with only 2 doses of CoronaVac, the level of antibody protection increased after the second vaccine. decreased to 56% in the third month. This data has proven that the 3rd dose vaccination is a good decision. Regardless of third-dose vaccine preference, all individuals receiving three doses of vaccine achieved protective antibody levels. The BioNTech vaccine applied in the third dose of vaccine showed a significant superiority in protection (both in terms of antibody level and disease status) compared to the third dose of CoronaVac vaccine. Those who received the third dose of BioNTech had antibody levels above the maximum measurable titer in 95% of the participants.”

Only 44 of the participants on the 3rd dose became ill due to COVID-19. However, none of them were hospitalized and had a mild outpatient illness. It is not yet clear whether it will be necessary to add the 4th dose to this application. After the third dose, the observation period, which will take 6 months in total, can give an answer to this. If it is determined that 1 more dose of BioNTech is necessary, It may be concluded that Sinovac is almost unnecessary.